Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer

British Journal of Cancer

Volumn 106, Issue 6, 2012, Pages 1033-1038

  Harder, J ^a   Ihorst, G ^b   Heinemann, V ^c   Hofheinz, R ^d   Moehler, M ^e   Buechler, P ^f   Kloeppel, G ^g   Rocken C ^g   Bitzer, M ^h   Boeck, S ^c   Endlicher, E ⁱ   Reinacher Schick, A ^j   Schmoor, C ^b   Geissler, M ^k  

^a Hegau Bodensee Klinikum   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^g UNIVERSITY OF KIEL   (Germany)

^h UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

ⁱ UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^j RUHR UNIVERSITY BOCHUM   (Germany)

^k KLINIKUM ESSLINGEN   (Germany)

more..

Author keywords

chemotherapy; growth factors; immunohistochemistry; pancreatic cancer

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; GENE AMPLIFICATION; GENE OVEREXPRESSION; HAND FOOT SYNDROME; HUMAN; IMMUNOHISTOCHEMISTRY; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TOXICITY; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84858296057     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.18     Document Type: Article

References (28)

1. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK, ToGA Trial Investigators (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697
2. Bednar F, Simeone DM (2011) Pancreatic cancer stem cell biology and its therapeutic implications. J Gastroenterol 46: 1345-1352
3. Buechler P, Reber HA, Buechler MC, Roth MA, Buechler MW, Friess H, Isacoff WH, Hines OJ (2001) Therapy for pancreatic cancer with a recombinant humanized anti HER2 antibody (herceptin). J Gastrointest Surg 5: 139-146 (Pubitemid 33652051)
4. Buechler P, Reber HA, Eibl G, Roth MA, Buechler MW, Friess H, Isacoff WH, Hines OJ (2005) Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy. Int J Oncol 27: 1125-1130
5. Burris H, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413 (Pubitemid 27251144)
6. Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM (2006) NCCN HER2 Testing in Breast Cancer Task Force. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 4(Suppl 3): S1-22; quiz S23-S24
7. Cartwright TH, Cohn A, Varkey JA, Chen YM, Szatrowski TP, Cox JV, Schulz JJ (2002) Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 20: 160-164 (Pubitemid 34032607)
8. Harder J, Waiz O, Otto F, Geissler M, Olschewski M, Weinhold B, Blum HE, Schmitt-Graeff A, Opitz OG (2009) EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol 15: 4511-4517
9. Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C (2008) Metaanalysis of randomized trials: evaluation of benefit from gemcitabinebased combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 8: 82
10. Hudis CA (2007) Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357: 39-51 (Pubitemid 47026733)
11. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28: 3617-3622
12. Kobayashi M, Ooi A, Oda Y, Nakanishi I (2002) Protein overexpression and gene amplification of c-erbB-2 in breast carcinomas: a comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissues. Hum Pathol 33: 21-28 (Pubitemid 34112949)
13. Larbouret C, Robert B, Bascoul-Mollevi C, Penault-Llorca F, Ho-Pun-Cheung A, Morisseau S, Navarro-Teulon I, Mach JP, Pèlegrin A, Azria D (2010) Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. Ann Oncol 21: 98-103
14. Liles JS, Arnoletti JP, Kossenkov AV, Mikhaylina A, Frost AR, Kulesza P, Heslin MJ, Frolov A (2011) Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma. Br J Cancer 105: 523-533
15. McDermott RS, Calvert P, Parker M, Webb G, Moulton B, McCaffrey J (2011) A phase II study of lapatinib and capecitabine in first-line treatment of metastatic pancreatic cancer (ICORG 08-39). J Clin Oncol 29(Suppl. 4): Abstract 315
16. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W, National Cancer Institute of Canada Clinical Trials Group (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical trials group. J Clin Oncol 25: 1960-1966 (Pubitemid 46972777)
17. Ooi A, Takehana T, Li X, Suzuki S, Kunitomo K, Iino H, Fujii H, Takeda Y, Dobashi Y (2004) Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 17: 895-904 (Pubitemid 38993773)
18. Philip PA, J Moinpour CM, Vaught NL, Goldman B, Redman MW, Millwood B, Lippman SM, Seay TE, Flynn PJ, O'Reilly EM, Rowland KM, Wong RP, Benedetti J, Blanke CD (2010) Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer. J Clin Oncol 28: 3605-3610
19. Rüschoff J, Nagelmeier I, Hofmann M, Henkel T, Stoss O (2009) ErbB2 diagnostics in breast cancer-an update. Pathologe 30(2): 147-155
20. Safran H, Iannitti D, Ramanathan R, Schwartz JD, Steinhoff M, Nauman C, Hesketh P, Rathore R, Wolff R, Tantravahi U, Hughes TM, Maia C, Pasquariello T, Goldstein L, King T, Tsai JY, Kennedy T (2004) Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 22: 706-712 (Pubitemid 40064730)
21. Safran H, Steinhoff M, Mangray S, Rathore R, King TC, Chai L, Berzein K, Moore T, Iannitti D, Reiss P, Pasquariello T, Akerman P, Quirk D, Mass R, Goldstein L, Tantravahi U (2001) Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol 24: 496-499 (Pubitemid 32959109)
22. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10 (Pubitemid 19099520)
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
24. Ukita Y, Kato M, Terada T (2002) Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization and immunohistochemistry. J Hepatol 36: 780-785 (Pubitemid 35177407)
25. Vaccaro V, Melisi D, Bria E, Cuppone F, Ciuffreda L, Pino MS, Gelibter A, Tortora G, Cognetti F, Milella M (2011) Emerging pathways and future targets for the molecular therapy of pancreatic cancer. Expert Opin Ther Targets 15: 1183-1196
26. Yamanaka Y, Friess H, Kobrin MS, Buechler M, Kunz J, Beger HG, Korc M (1993) Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol 24: 1127-1134 (Pubitemid 23306246)
27. Yau TK, Sze H, Soong IS, Hioe F, Khoo US, Lee AW (2008) HER2 overexpression of breast cancers in Hong Kong: prevalence and concordance between immunohistochemistry and in-situ hybridisation assays. Hong Kong Med J 14: 130-135
28. Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J, Needle M, Abbruzzese JL (2004) Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 22: 2610-2616 (Pubitemid 41103748)